

Finding safer, cleaner and greener products



# TOPICAL ANTISEPTIC GEL

## THE WOUND CARE MIRACLE

Introducing My-shield® Topical Antiseptic Gel, a USA, GLP (Good Laboratory Practice) manufactured nano silicone/based FDA approved, over-the-counter, 0.13% Benzalkonium chloride pre-priority formulation.

Designed specially to promote rapid infection free healing of minor cuts, deep wounds, abrasions and burns and over current prescription and over-the-counter products available in the USA today.

My-shield® Topical Antiseptic Gel was developed to provide long-lasting, alcohol-free protection from germs when applied to minor cuts, deep wounds, abrasions and burns. With the addition of our proprietary formula Zetrisil®, it not only controls wound bacterial contamination, it promotes rapid wound healing & prevents future bacterial wound re-infections.

Formulated with

**Zetrisil**<sup>TM</sup>

A PROPRIETARY SILICONE QUATERNARY SOLUTION



### WHAT IS ZETRISIL® AND HOW DOES IT HELP WITH WOUND HEALING?

Zetrisil® is a proprietary nano-based silicone compound combined with conventional quaternary ammonium compounds, that effectively protects and/or "shields" the effected area from bacterial contamination, by way of a long-lasting, cationic charged, anti microbial nano silicone coating.

# CLINICAL PRODUCT TRIAL RESULTS

## SUBJECT #1:

92 year old female still living in her own home under the care of her son within her home and her daughter across the street. Patient is known to be protein malnourished with Stage III Chronic Renal Failure.

## DATE OF TRIAL:

Commenced on the 26th of April, 2019

## TRIAL CONDUCTED BY:

Choisser Medical Group, Orange Park, Florida, USA

## PHYSICIAN OVERSEEING TRIAL:

William V. Choisser, M.D.  
Shane McClanahan, PA-C via housecall services

## RELEVANT PRESCRIPTION MEDICATION:

- Eliquis® (blood thinner) due to recent DVT and pulmonary embolism
- Spironolactone & Lasix diuretics for CHF
- Levothyroxine to treat Hypothyroidism

## RELEVANT PATIENT PHYSICAL CONDITION:

Advanced age structural and functional skin degeneration, large 15 cm x 4 cm laceration to the right shin with partial depth skin & tissue loss occurred on 4-21-19 and treated by family members with Triple Antibiotic Ointment for 4 days. Physician Assistant Shane McClanahan was contacted on day 5 and My-shield® Topical Antiseptic Gel was applied liberally with Keflex antibiotic administered due to early cellulitis.

## TREATMENT DETAILS:

My-shield® Topical Antiseptic Gel was applied liberally over the entire wound, covered with sterile petrolatum mesh (note crosshatched pattern on new tissue) and covered with Teflon non-adherent dressing and padded with dry gauze and wrapped with roller gauze to avoid tape contacting the skin. The treatment process was repeated once daily from the 26th of April, 2019 to the 3rd of May, 2019 when the Teflon dressing was discontinued due to minimal wound exudate. My-shield® Topical Antiseptic Gel was continued through May 20th, 2019 (complete wound closure) with recommended follow up application of My-shield® Topical Antiseptic Gel once daily for 7 more days. Wound debridement was never attempted due to patient's emotional state and was found to be completely unnecessary due to the speed of wound remodeling, closure and healing.

## OBSERVATIONS TO THE RAPID IMPROVEMENT IN THE PATIENT'S WOUND CAN BE ATTRIBUTED TO THE FOLLOWING MECHANISMS:

- Improved functional parallel formation of collagen Type I production.
- Reduction in bacterial and or bacterial biofilm contamination, thus reducing bacterial produced endotoxins that may slow wound healing & tissue regeneration
- Upregulation of TGF beta and fibrillin, closed the wound openings quickly.
- Stimulated protein production and growth factors, no hypertrophic scarring or keloid formation on the healing tissue.

## PHOTOS DOCUMENTING TREATMENT:

The treatment process was repeated once daily from the 26th of April, 2019 to the 3rd of May, 2019 when the Teflon dressing was discontinued due to minimal wound exudate. My-shield® Topical Antiseptic Gel was continued through May 27th, 2019



4/26/19



5/03/19



5/20/19



5/27/19

Distributed By: Germs Rx 888-437-6779 [myshield@gersrx.com](mailto:myshield@gersrx.com) Peoria, Arizona

**SUBJECT #3:**

60 year old Female Registered Nurse

**DATE OF TRIAL:**

Commenced on the 27th of August, 2019

**TRIAL CONDUCTED BY:**

Choisser Medical Group, Orange Park, Florida, USA

**PHYSICIAN OVERSEEING TRIAL:**

William V. Choisser, M.D.

Shane McClanahan, PA-C

**RELEVANT PATIENT PHYSICAL CONDITION:**

Patient sustained a deep second degree burn on the right thumb from a hot metal oven rack. No other issues were present.

**TREATMENT DETAILS:**

My-shield® Topical Antiseptic was applied once daily and covered with a Telfa bandaid. When the wound no longer had any weeping, the bandaid was left off and My-shield® Topical Antiseptic was allowed to dry on top of the wound until fully healed.

**OBSERVATIONS TO THE RAPID IMPROVEMENT IN THE PATIENT'S BURN CAN BE ATTRIBUTED TO THE FOLLOWING MECHANISMS:**

- Reduction in swelling and redness within 4 days
- Reduction in bacterial and/or bacterial biofilm contamination, thus reducing bacteria produced endotoxins that may slow wound healing and tissue regeneration
- Burn fully healed in 9 days.

**PHOTOS DOCUMENTING TREATMENT:**

The treatment process was repeated once daily from August 27th, 2019 to September 5th, 2019



8/27/19



8/31/19 (4 Days)



9/05/19 (9 Days)

Distributed By: Germs Rx 888-437-6779 [myshield@germsrx.com](mailto:myshield@germsrx.com) Peoria, Arizona